YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
A month has gone by since the last earnings report for Black Diamond (BDTX). Shares have added about 9.4% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up…
Black Diamond Therapeutics BDTX is widening the opportunity set for silevertinib by pushing beyond lung cancer and into glioblastoma, a move that leans on the same core attribute that has driven investor interest so far: central nervous sy…
Black Diamond Therapeutics BDTX delivered a modest first-quarter earnings beat, but the stock’s story remains almost entirely clinical. Investors are underwriting one main question: can silevertinib deliver durable, differentiated benefit…
Black Diamond Therapeutics BDTX is building its equity story around one drug, silevertinib, a brain-penetrant, fourth-generation EGFR inhibitor being studied in EGFR–mutant non-small cell lung cancer. The newest phase II update in May 2026…
Black Diamond Therapeutics BDTX shares fell 35.8% as investors appeared to take a mixed view of the latest phase II update for the company’s lead candidate, silevertinib, being evaluated for first-line non-small cell lung cancer (NSCLC) pa…
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today…
(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company, announced positive results with 15.2 months of median Progression-free Survival from its Phase 2 trial of Silevertinib in frontline or 1L non-small cel…
Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent and manageable AE pr…
(RTTNews) - In today's gainers' list, we cover HCW Biologics, its upcoming catalysts and going concern risks; Silexion's development progress of its lead drug candidate SIL204; Immunovant's encouraging rheumatoid arthritis data; why invest…
(RTTNews) - As hedge fund tycoon George Soros once said, "It's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong." The following biotech stocks were am…
Black Diamond Therapeutics BDTX is building its thesis around a single, brain-penetrant EGFR inhibitor, silevertinib, with early clinical activity across a wide range of EGFR mutations and a safety profile that has been manageable and cons…
Black Diamond Therapeutics BDTX is a clinical-stage oncology company with a story that is simple and high stakes. The upside case is tied to one drug, silevertinib, and the market’s willingness to underwrite its next data points. Early res…
Black Diamond Therapeutics BDTX is a clinical-stage oncology company with an investment story that largely runs through a single program: silevertinib, its brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKe…
Black Diamond Therapeutics, Inc. BDTX offers a high-leverage oncology setup built around one primary value driver: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) inhibitor in phase II for EGFR-mu…
Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) inhibitor being studied in EGFR-mutant non-…
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is on our list of the top 10 stocks under $5 that could triple.Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program As of March 17, 2026, Black Diamo…
Day One Biopharmaceuticals DAWN has signed a definitive agreement with France-based Servier. Per the terms, Servier will acquire all outstanding shares of DAWN at $21.50 each, valuing the deal at about $2.5 billion. Post this acquisition,…
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalonta…
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks. TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX t…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Black Diamond Therapeutics, Inc. BDTX: This clinical-stage oncology company has seen the Zacks Consensus Estimate for its current year earnings increasing 4.4% over t…
Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS d…
(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) will host a webcast presentation on December 3, 2025, at 8:00 am ET to highlight results from its ongoing Phase 2 clinical trial of silevertinib in first-line non-small cell lung cancer (…
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target famili…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANI Pharmaceuticals (ANIP) is a stock that can certainly grab the attention of many investors, but do it…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ANI Pharmaceuticals (ANIP) one of those stocks right now? A quick glance at the company's year-to-da…
Shares of Black Diamond (BDTX) have been strong performers lately, with the stock up 22.9% over the past month. The stock hit a new 52-week high of $4.65 in the previous session. Black Diamond has gained 115.9% since the start of the year…
As the U.S. market faces a challenging period with tech stocks under pressure and major indices experiencing losses, investors are exploring alternative opportunities to diversify their portfolios. Penny stocks, though often seen as remnan…
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, toda…
ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025…
Investors will focus on updates on lead pipeline candidate silevertinib when Black Diamond Therapeutics BDTX reports third-quarter results shortly. The Zacks Consensus Estimate for loss per share is pegged at 22 cents. Earnings estimate fo…
Black Diamond Therapeutics, Inc. BDTX is developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. BDTX’s lead drug silevertinib is a brain-penetrant, fourth-generation epidermal growth factor rece…
Black Diamond Therapeutics, Inc. BDTX performance has been outstanding in 2025. Shares of this clinical-stage oncology company hit a 52-week high of $4.1 on Oct. 8. Year to date, BDTX shares have skyrocketed 86.4% compared with the industr…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Medpace (MEDP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favora…
A strong stock as of late has been Black Diamond (BDTX). Shares have been marching higher, with the stock up 28.5% over the past month. The stock hit a new 52-week high of $4.03 in the previous session. Black Diamond has gained 83.2% since…
Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting epidermal growth factor receptor…
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best stocks with the highest upside potential. Guggenheim assumed coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with a “Buy” rating and a price target of $8.00, imply…